(dailyRx News) About one in five women diagnosed with breast cancer have too much of a protein called HER2, which makes the cancer more likely to grow faster and return. New research has some good news for women with this cancer.

In a phase ll trial, all but a few women with HER-2 positive breast cancer were disease-free more than three years after receiving mild chemotherapy and the targeted therapy, Herceptin (trastuzumab).

The authors of this study suggested these findings should be regarded as a new standard of care for treating small HER2-positive breast cancers.

Read more from RxWiki HERE.